BioInvent holds Capital Markets Day in Stockholm
Detailed review of BioInvent’s programmes, including its lead products, BI-204 (cardiovascular disease) and TB-402 (anti-Factor VIII)Lund, Sweden–8 November 2011 – BioInvent International AB (OMXS: BINV) will hold its first Capital Markets Day for investors, analysts and media today. The event will be hosted by Svein Mathisen, CEO, and Sten Westerberg, VP IR of BioInvent. They will be supported by members of the senior team, including Steven Glazer MD, Senior Vice President, Development, Martin Wiles, Senior Vice President, Business Development, Björn Frendéus, Vice President,